Overview

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

Status:
Not yet recruiting
Trial end date:
2023-12-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC